These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 29922663)

  • 1. The Medical Management of Gastro-Oesophageal Reflux Disease.
    Sharma N; Ho KY
    Inflamm Intest Dis; 2016 Jul; 1(2):96-99. PubMed ID: 29922663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oesophageal and gastric pH profiles in patients with gastro-oesophageal reflux disease and Barrett's oesophagus treated with proton pump inhibitors.
    Gerson LB; Boparai V; Ullah N; Triadafilopoulos G
    Aliment Pharmacol Ther; 2004 Sep; 20(6):637-43. PubMed ID: 15352912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tobacco smoking, alcohol consumption and gastro-oesophageal reflux disease.
    Ness-Jensen E; Lagergren J
    Best Pract Res Clin Gastroenterol; 2017 Oct; 31(5):501-508. PubMed ID: 29195669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Temporal trends of Barrett's oesophagus and gastro-oesophageal reflux and related oesophageal cancer over a 10-year period in England and Wales and associated proton pump inhibitor and H2RA prescriptions: a GPRD study.
    Alexandropoulou K; van Vlymen J; Reid F; Poullis A; Kang JY
    Eur J Gastroenterol Hepatol; 2013 Jan; 25(1):15-21. PubMed ID: 23022985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GORD and Barrett's oesophagus after bariatric procedures: multicentre prospective study.
    Genco A; Castagneto-Gissey L; Gualtieri L; Lucchese M; Leuratti L; Soricelli E; Casella G
    Br J Surg; 2021 Dec; 108(12):1498-1505. PubMed ID: 34738106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological management of gastro-oesophageal reflux disease.
    Klinkenberg-Knol EC; Festen HP; Meuwissen SG
    Drugs; 1995 May; 49(5):695-710. PubMed ID: 7601011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Barrett's oesophagus: optimal strategies for prevention and treatment.
    Fass R; Sampliner RE
    Drugs; 2003; 63(6):555-64. PubMed ID: 12656653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease.
    Hatlebakk JG; Berstad A
    Clin Pharmacokinet; 1996 Nov; 31(5):386-406. PubMed ID: 9118586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic review with meta-analysis: risk factors for Barrett's oesophagus in individuals with gastro-oesophageal reflux symptoms.
    Eusebi LH; Telese A; Cirota GG; Haidry R; Zagari RM; Bazzoli F; Ford AC
    Aliment Pharmacol Ther; 2021 May; 53(9):968-976. PubMed ID: 33705573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacotherapy for chronic gastro-oesophageal reflux disease and Barrett's oesophagus.
    Wurm P; de Caestecker J
    Expert Opin Pharmacother; 2003 Jul; 4(7):1049-61. PubMed ID: 12831333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of oesophageal cancer in Barrett's oesophagus and gastro-oesophageal reflux.
    Solaymani-Dodaran M; Logan RF; West J; Card T; Coupland C
    Gut; 2004 Aug; 53(8):1070-4. PubMed ID: 15247170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving the diagnosis and management of GORD in adults.
    Hopper AD
    Practitioner; 2015 Apr; 259(1781):27-32, 3. PubMed ID: 26529827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review article: is Helicobacter pylori status relevant in the management of GORD?
    Vigneri S; Termini R; Savarino V; Pace F
    Aliment Pharmacol Ther; 2000 Oct; 14 Suppl 3():31-42. PubMed ID: 11050485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transient lower oesophageal sphincter relaxations play an insignificant role in gastro-oesophageal reflux to the proximal oesophagus.
    Grossi L; Ciccaglione AF; Marzio L
    Neurogastroenterol Motil; 2001 Oct; 13(5):503-9. PubMed ID: 11696112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gastro-oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors.
    Katz PO; Anderson C; Khoury R; Castell DO
    Aliment Pharmacol Ther; 1998 Dec; 12(12):1231-4. PubMed ID: 9882031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transient lower oesophageal sphincter relaxations--a pharmacological target for gastro-oesophageal reflux disease?
    Hirsch DP; Tytgat GN; Boeckxstaens GE
    Aliment Pharmacol Ther; 2002 Jan; 16(1):17-26. PubMed ID: 11856074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progress with novel pharmacological strategies for gastro-oesophageal reflux disease.
    Tonini M; De Giorgio R; De Ponti F
    Drugs; 2004; 64(4):347-61. PubMed ID: 14969571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bile reflux gastritis and Barrett's oesophagus: further evidence of a role for duodenogastro-oesophageal reflux?
    Dixon MF; Neville PM; Mapstone NP; Moayyedi P; Axon AT
    Gut; 2001 Sep; 49(3):359-63. PubMed ID: 11511557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease.
    van Pinxteren B; Numans ME; Bonis PA; Lau J
    Cochrane Database Syst Rev; 2006 Jul; (3):CD002095. PubMed ID: 16855986
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.